Supreme Court Turns Away CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court declined to hear CareDx's appeal against Natera in a false-advertising case, leaving a lower court ruling intact.
The U.S. Supreme Court has refused to take up CareDx's appeal in its ongoing false-advertising battle with Natera, a decision that closes a major legal escape hatch for CareDx and keeps an earlier ruling firmly in place. When the high court declines to hear a case, it effectively lets the lower court's judgment stand — and that's not good news for CareDx.
Natera, the genetic testing company behind the Prospera transplant rejection test, has been locked in litigation with rival CareDx over claims tied to how each company marketed its kidney transplant monitoring products. The dispute centers on false-advertising allegations — the kind of legal fight that can carry serious financial and reputational consequences in a competitive diagnostics market.
Read more BofA Keeps Apple Buy Rating, Sees AI Upgrade Cycle Ahead →
For traders watching NTRA, this development removes a layer of legal uncertainty that had been hanging over the stock. A Supreme Court rejection isn't a ruling on the merits, but it signals that CareDx has run out of appellate runway on this particular challenge. Natera keeps its legal position intact, which is a net positive heading into whatever comes next in the underlying case.
CareDx, meanwhile, faces a tougher road. With the high court off the table, the company will need to deal with the consequences of the lower court's findings directly. In a niche but high-stakes diagnostics space, courtroom outcomes can shift competitive dynamics fast — and this one arguably tilts the board toward Natera.
Continue reading at Yahoo Finance
